nach oben

Reactions Weekly

Erschienen in:

01.07.2019 | Case report

Docetaxel/pertuzumab/trastuzumab

Allergy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In a retrospective study (of patient records between 2013−2016) involving 75 patients, a patient [age and sex not stated] was described, who developed allergy to trastuzumab [Herceptin], docetaxel and pertuzumab [dosages and routes not stated] treatment for HER-2 positive metastatic breast cancer. The patient's treatment with trastuzumab, docetaxel and pertuzumab was stopped [duration of treatments to reaction onset and outcome not stated]. …

Suleman K, et al. Retrospective review of Her2 positive metastatic breast cancer patients who received Pertuzumab and Herceptin as a first line therapy at KFSH&RC (single institute experience) from 2013 to 2016. Breast 44 (Suppl. 1): S64 abstr. P144, Apr 2018. Available from: URL: http://doi.org/10.1016/S0960-9776%2819%2930245-0 [abstract] - Saudi Arabia

Titel: Docetaxel/pertuzumab/trastuzumab
Allergy: case report
Publikationsdatum: 01.07.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-64516-6

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Docetaxel/pertuzumab/trastuzumab

Allergy: case report

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Leflunomide

Adalimumab

Fingolimod/interferon-β-1a

Nilotinib

Alzheimer disease and related dementias with anticholinergics

Dexamethasone